| EPIC | EAH |
| Sector | Pharma and Biotech |
| ISIN | GB0032036807 |
| Market Sector | AIM |
| Market Segment | ASX1 |
| Main Indices | FTSE AIM All-Share |
| Country of register | Great Britain |
| Currency | British Pound |
| Market Cap | £65.73m |
| NMS | 1,500 |
| Shares in issue | 67.76m |
| Date Listed | 26-Sep-1995 |
| Currency | UK Pounds |
| Share Price | 97.00p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 114.00 |
| 52 Week Low | 57.00 |
| Volume | 0 |
| Shares Issued | 67.76m |
| Market Cap | £65.73m |
| Beta | 0.01 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 1 |
| Buy | 1 |
| Neutral | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 2 |

| Latest | Previous | |
|---|---|---|
| Final | Final | |
| Ex-Div | 23-Sep-21 | 26-Sep-19 |
| Paid | 22-Oct-21 | 16-Oct-19 |
| Amount | 1.00p | 7.04p |
| CFO | Christopher Wilks |
| CEO | David Hallas |
You are here: research